Literature DB >> 25013537

Neurotoxin waste from drawing product through the vial stopper.

Joe Niamtu1.   

Abstract

Botulinum toxin injection is the most common cosmetic surgery procedure in the world. Current technique requires reconstitution that can produce product waste resulting in significant loss of profit as well as inaccuracy of actual units injected. By random sampling of "used empty" vials, it was shown that an average of 5 units are potentially wasted by the conventional methods of drawing up the product with a needle through the stopper of an inverted vial. Depending on the pricing and dilution of the product, this can result in a profit loss of $50 to $60 per vial, which can quickly add up to tens of thousands of dollars in a busy practice. Removing the stopper, tilting the vial, and aspirating the last residual with a small gauge needle can result in significant savings. Finally, this residual was calculated at a five-percent loss, which results in an inaccuracy of actual units delivered.

Year:  2014        PMID: 25013537      PMCID: PMC4086531     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  5 in total

Review 1.  Aesthetic uses of botulinum toxin A.

Authors:  J Niamtu
Journal:  J Oral Maxillofac Surg       Date:  1999-10       Impact factor: 1.895

2.  Maximizing extraction of botulinum toxin type A from vials.

Authors:  Dennis D Dykstra; J Michael Wieting; John McGuire; Thomas Kowalkowski
Journal:  Arch Phys Med Rehabil       Date:  2002-11       Impact factor: 3.966

3.  Sterility assessment of multiple use botulinum A exotoxin vials: a prospective simulation.

Authors:  Murad Alam; Simon S Yoo; David A Wrone; Lucile E White; John Y S Kim
Journal:  J Am Acad Dermatol       Date:  2006-08       Impact factor: 11.527

4.  Recommendations and current practices for the reconstitution and storage of botulinum toxin type A.

Authors:  Austin Liu; Alastair Carruthers; Joel L Cohen; William P Coleman; Jeffrey S Dover; C William Hanke; Ronald L Moy; David M Ozog
Journal:  J Am Acad Dermatol       Date:  2011-11-04       Impact factor: 11.527

5.  Botulinum toxin A: a review of 1,085 oral and maxillofacial patient treatments.

Authors:  Joseph Niamtu
Journal:  J Oral Maxillofac Surg       Date:  2003-03       Impact factor: 1.895

  5 in total
  3 in total

1.  Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.

Authors:  Jürgen Frevert
Journal:  Drugs R D       Date:  2015-03

Review 2.  Botulinum neurotoxin formulations: overcoming the confusion.

Authors:  Souphiyeh Samizadeh; Koenraad De Boulle
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-05-30

3.  A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus.

Authors:  Gerard E Francisco; Alexander Balbert; Ganesh Bavikatte; Djamel Bensmail; Stefano Carda; Thierry Deltombe; Nathalie Draulans; Steven Escaldi; Raphael Gross; Jorge Jacinto; Nicholas Ketchum; Franco Molteni; Susana Moraleda; Michael W ODell; Rajiv Reebye; Patrik Säterö; Monica Verduzco-Gutierrez; Heather Walker; Jörg Wissel
Journal:  J Rehabil Med       Date:  2021-01-01       Impact factor: 2.912

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.